Comerica Bank decreased its position in Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 2.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,074 shares of the health services provider’s stock after selling 307 shares during the quarter. Comerica Bank’s holdings in Amedisys were worth $1,475,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in AMED. First Horizon Advisors Inc. raised its stake in Amedisys by 862.5% in the 2nd quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock valued at $40,000 after purchasing an additional 345 shares during the last quarter. Neo Ivy Capital Management acquired a new position in Amedisys in the 2nd quarter valued at about $44,000. Covestor Ltd raised its stake in Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after purchasing an additional 152 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Amedisys in the 1st quarter valued at about $68,000. Finally, Field & Main Bank raised its stake in Amedisys by 17.7% in the 2nd quarter. Field & Main Bank now owns 665 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 96.17% of the company’s stock.
Amedisys Stock Up 1.7 %
AMED opened at $95.47 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.06 and a current ratio of 1.06. Amedisys, Inc. has a 1 year low of $79.30 and a 1 year high of $179.91. The firm has a 50 day moving average price of $86.16 and a 200 day moving average price of $102.44. The company has a market cap of $3.10 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 2.30 and a beta of 0.96.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the stock. SVB Leerink dropped their price objective on shares of Amedisys from $96.00 to $85.00 and set a “market perform” rating for the company in a research note on Thursday, January 5th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Amedisys from $175.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, October 24th. Oppenheimer cut their price objective on shares of Amedisys from $145.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday. Cowen cut their price objective on shares of Amedisys to $103.00 in a report on Friday, November 4th. Finally, StockNews.com upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a report on Wednesday, January 18th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $134.19.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.